RPG Life Sciences Limited has informed the Exchange that Record date for the purpose of DI is 19-Jun-2026.
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
RPG Life Sciences reported FY2025-26 standalone revenue of Rs. 70,752 lakhs, up 8.3% from Rs. 65,343 lakhs in FY2024-25. However, profit after tax declined significantly to Rs. 11,517 lakhs from Rs. 18,324 lakhs (down 37%), driven by lower exceptional items. The prior year included a one-time gain of Rs. 10,018 lakhs from land assignment. This year, exceptional items included Rs. 12,623 lakhs from land sale, Rs. 2,475 lakhs net insurance recovery from a fire incident, partially offset by Rs. 1,169 lakhs labour code impact and Rs. 916 lakhs intangible asset write-off. The Board recommended a dividend of Rs. 24 per share (300%), subject to shareholder approval. Auditor gave an unmodified (clean) opinion. The company also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for 5 years.
The 37% PAT decline despite 8% revenue growth reflects the absence of large one-time gains seen in the previous year. The strong dividend payout signals management confidence, but investors should focus on core operating performance excluding exceptional items when evaluating the stock.